Imunon, Inc.
IMNN Nasdaq· Pharmaceutical Preparations
Last close · Oct 27, 2026
$0.88
KIRA · Stoqly’s AI analyst, in plain words
- Imunon, Inc. lost $14.5M in fiscal 2025.
- Free cash flow was −$14.2M in fiscal 2025, — of revenue.
Market cap
$4.6M
P/E
—
Revenue
—
Net income
−$14.5M
Free cash flow
−$14.2M
Operating margin
—
Imunon, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$14.5M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Imunon, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 31, 2026
- Legal name
- Imunon, Inc.
- CIK
- 0000749647
Imunon, Inc. · IMNN
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $0.5M | $0.5M | — | — | — |
| Revenue growth | 0.0% | 0.0% | — | — | — |
| Operating margin | −4,201.4% | −4,984.3% | — | — | — |
| Net income | −$20.8M | −$35.9M | −$19.5M | −$18.6M | −$14.5M |
| Net margin | −4,153.9% | −7,179.6% | — | — | — |
| Diluted EPS | −$3.83 | −$5.03 | −$2.16 | −$16.94 | −$6.83 |
| Cash | |||||
| Cash from operations | −$16.2M | −$23.1M | −$19.0M | −$18.9M | −$13.9M |
| Capital expenditure | $0.3M | $0.3M | $0.5M | $0.0M | $0.3M |
| Free cash flow | −$16.5M | −$23.4M | −$19.5M | −$18.9M | −$14.2M |
| FCF margin | −3,307.0% | −4,672.9% | — | — | — |
| Share count change | 154.7% | 31.6% | 26.6% | −87.9% | 93.2% |
| Debt and strength | |||||
| Cash and short-term investments | $49.4M | $32.7M | $15.6M | $5.9M | $8.8M |
| Debt incl. finance leases | — | $6.0M | — | — | — |
| Shareholders' equity | $55.8M | $29.3M | $13.4M | $4.2M | $7.1M |
| Current ratio | 7.7x | 3.7x | 2.5x | 1.7x | 2.3x |
| Interest coverage | −36.9x | −5.0x | −106.7x | — | — |
| Returns and quality | |||||
| Return on capital | — | −765.7% | — | — | — |
| Return on equity | −55.8% | −84.3% | −91.4% | −211.2% | −256.4% |
| Return on tangible equity | −37.2% | −122.4% | −145.8% | −438.7% | −205.3% |
| Piotroski F-score | 3 | 2 | — | — | — |
| Altman Z'' | −9.3 | −25.0 | −59.3 | −146.7 | −115.1 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
1 insider
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Imunon, Inc. · IMNN
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.88 a share, the company is worth $4.6M.
Source: SEC EDGAR XBRL filings (CIK 0000749647). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.